Explore the Potential with AI-Driven Innovation
This comprehensive focused library is produced on demand with state-of-the-art virtual screening and parameter assessment technology driven by Receptor.AI drug discovery platform. This approach outperforms traditional methods and provides higher-quality compounds with superior activity, selectivity and safety.
From a virtual chemical space containing more than 60 billion molecules, we precisely choose certain compounds. Our collaborator, Reaxense, aids in their synthesis and provision.
The library includes a list of the most effective modulators, each annotated with 38 ADME-Tox and 32 physicochemical and drug-likeness parameters. Furthermore, each compound is shown with its optimal docking poses, affinity scores, and activity scores, offering a detailed summary.
We employ our advanced, specialised process to create targeted libraries.
Fig. 1. The sreening workflow of Receptor.AI
Our methodology leverages molecular simulations to examine a vast array of proteins, capturing their dynamics in both isolated forms and in complexes with other proteins. Through ensemble virtual screening, we thoroughly account for the protein's conformational mobility, identifying critical binding sites within functional regions and distant allosteric locations. This detailed exploration ensures that we comprehensively assess every possible mechanism of action, with the objective of identifying novel therapeutic targets and lead compounds that span a wide spectrum of biological functions.
Key features that set our library apart include:
partner
Reaxense
upacc
P22415
UPID:
USF1_HUMAN
Alternative names:
Class B basic helix-loop-helix protein 11; Major late transcription factor 1
Alternative UPACC:
P22415; B2RBZ4; Q5SY46; Q7Z5Y1
Background:
Upstream stimulatory factor 1 (USF1), encoded by the gene P22415, is a transcription factor that binds to symmetrical DNA sequences known as E-boxes. This protein plays a crucial role in the regulation of various viral and cellular promoters. It is alternatively named Class B basic helix-loop-helix protein 11 or Major late transcription factor 1, highlighting its significance in transcriptional control.
Therapeutic significance:
USF1's involvement in familial combined hyperlipidemia, a disorder marked by elevated serum cholesterol and triglycerides, underscores its potential as a target for therapeutic intervention. Understanding the role of Upstream stimulatory factor 1 could open doors to potential therapeutic strategies.